Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H39N7O12.HNO3 |
| Molecular Weight | 644.5869 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.[H][C@]2(O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1NC)[C@H](O[C@@]3([H])[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N)O[C@@H](C)[C@]2(O)C=O
InChI
InChIKey=RVLYTJGYOXDYAG-RMIBZTJPSA-N
InChI=1S/C21H39N7O12.HNO3/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;2-1(3)4/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);(H,2,3,4)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;/m0./s1
DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf
Streptomycin is a water-soluble aminoglycoside derived from Streptomyces griseus. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
Streptomycin is indicated for the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map03010 |
|||
Target ID: CHEMBL360 |
5.36 µM [IC50] | ||
Target ID: CHEMBL612748 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | STREPTOMYCIN SULFATE Approved UseStreptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1946 |
|||
| Curative | STREPTOMYCIN SULFATE Approved UseStreptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1946 |
|||
| Curative | STREPTOMYCIN SULFATE Approved UseStreptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1946 |
|||
| Curative | STREPTOMYCIN SULFATE Approved UseStreptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1946 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
42.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560193/ |
18 mg/kg single, intramuscular dose: 18 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
STREPTOMYCIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
264 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560193/ |
18 mg/kg single, intramuscular dose: 18 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
STREPTOMYCIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560193/ |
18 mg/kg single, intramuscular dose: 18 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered: |
STREPTOMYCIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Co-administed with:: Doxycycline(100 mg oral; 2/day) Sources: Page: p.2066 |
unhealthy, 12–70 n = 94 Health Status: unhealthy Condition: Brucellosis Age Group: 12–70 Sex: M+F Population Size: 94 Sources: Page: p.2066 |
Disc. AE: Heartburn, Fatigue... AEs leading to discontinuation/dose reduction: Heartburn (1.06%) Sources: Page: p.2066Fatigue (1.06%) |
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Co-administed with:: lsoniazid(300 mg iv; 1/day) Sources: Page: p.47rifampicin(600 mg iv; 1/day) pyrazinamide(2 g iv; 1/day) |
unhealthy, 15-70 n = 119 Health Status: unhealthy Condition: Pulmonary tuberculosis Age Group: 15-70 Sex: M+F Population Size: 119 Sources: Page: p.47 |
Disc. AE: Hypersensitivity, Disorder vestibular... AEs leading to discontinuation/dose reduction: Hypersensitivity (1.7%) Sources: Page: p.47Disorder vestibular (0.84%) |
1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 13 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 25–76 Sex: M+F Population Size: 13 Sources: Page: p.1539 |
Other AEs: Ototoxicity, Nephrotoxicity... Other AEs: Ototoxicity Sources: Page: p.1539Nephrotoxicity Vestibular toxicity |
1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 3 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 25–76 Sex: M+F Population Size: 3 Sources: Page: p.1539 |
Other AEs: Ototoxicity, Nephrotoxicity... Other AEs: Ototoxicity Sources: Page: p.1539Nephrotoxicity Vestibular toxicity |
800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.1539 |
unhealthy, 26–73 n = 10 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 26–73 Sex: M+F Population Size: 10 Sources: Page: p.1539 |
Other AEs: Ototoxicity, Nephrotoxicity... |
800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.1539 |
unhealthy, 26–73 n = 6 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 26–73 Sex: M+F Population Size: 6 Sources: Page: p.1539 |
Other AEs: Ototoxicity, Nephrotoxicity... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Fatigue | 1.06% Disc. AE |
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Co-administed with:: Doxycycline(100 mg oral; 2/day) Sources: Page: p.2066 |
unhealthy, 12–70 n = 94 Health Status: unhealthy Condition: Brucellosis Age Group: 12–70 Sex: M+F Population Size: 94 Sources: Page: p.2066 |
| Heartburn | 1.06% Disc. AE |
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Co-administed with:: Doxycycline(100 mg oral; 2/day) Sources: Page: p.2066 |
unhealthy, 12–70 n = 94 Health Status: unhealthy Condition: Brucellosis Age Group: 12–70 Sex: M+F Population Size: 94 Sources: Page: p.2066 |
| Disorder vestibular | 0.84% Disc. AE |
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Co-administed with:: lsoniazid(300 mg iv; 1/day) Sources: Page: p.47rifampicin(600 mg iv; 1/day) pyrazinamide(2 g iv; 1/day) |
unhealthy, 15-70 n = 119 Health Status: unhealthy Condition: Pulmonary tuberculosis Age Group: 15-70 Sex: M+F Population Size: 119 Sources: Page: p.47 |
| Hypersensitivity | 1.7% Disc. AE |
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Co-administed with:: lsoniazid(300 mg iv; 1/day) Sources: Page: p.47rifampicin(600 mg iv; 1/day) pyrazinamide(2 g iv; 1/day) |
unhealthy, 15-70 n = 119 Health Status: unhealthy Condition: Pulmonary tuberculosis Age Group: 15-70 Sex: M+F Population Size: 119 Sources: Page: p.47 |
| Nephrotoxicity | 1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 13 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 25–76 Sex: M+F Population Size: 13 Sources: Page: p.1539 |
|
| Ototoxicity | 1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 13 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 25–76 Sex: M+F Population Size: 13 Sources: Page: p.1539 |
|
| Vestibular toxicity | 1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 13 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 25–76 Sex: M+F Population Size: 13 Sources: Page: p.1539 |
|
| Nephrotoxicity | 1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 3 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 25–76 Sex: M+F Population Size: 3 Sources: Page: p.1539 |
|
| Ototoxicity | 1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 3 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 25–76 Sex: M+F Population Size: 3 Sources: Page: p.1539 |
|
| Vestibular toxicity | 1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: Page: p.1539 |
unhealthy, 25–76 n = 3 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 25–76 Sex: M+F Population Size: 3 Sources: Page: p.1539 |
|
| Nephrotoxicity | 800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.1539 |
unhealthy, 26–73 n = 10 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 26–73 Sex: M+F Population Size: 10 Sources: Page: p.1539 |
|
| Ototoxicity | 800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.1539 |
unhealthy, 26–73 n = 10 Health Status: unhealthy Condition: Mycobacterium avium complex Age Group: 26–73 Sex: M+F Population Size: 10 Sources: Page: p.1539 |
|
| Nephrotoxicity | 800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.1539 |
unhealthy, 26–73 n = 6 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 26–73 Sex: M+F Population Size: 6 Sources: Page: p.1539 |
|
| Ototoxicity | 800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.1539 |
unhealthy, 26–73 n = 6 Health Status: unhealthy Condition: Mycobacterium tuberculosis Age Group: 26–73 Sex: M+F Population Size: 6 Sources: Page: p.1539 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The evaluation of neomycin and other antimicrobial agents of bacterial and fungal origin, and substances from higher plants. | 1949 Dec 14 |
|
| [The pathogenesis of tuberculous infection and the prognosis in tuberculous meningitis in children after streptomycin therapy]. | 1952 Mar 15 |
|
| Antimicrobial agents from marine algae. | 1975 Mar |
|
| [The intratympanic treatment of Menière's disease with ototoxic antibiotics. A follow-up study of 55 cases (author's transl)]. | 1977 May |
|
| Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. | 1991 Nov-Dec |
|
| Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases. | 1992 |
|
| Chlorpromazine: a drug potentially useful for treating mycobacterial infections. | 1992 |
|
| [A successfully treated case of acute renal failure due to acute immune hemolytic anemia and nontraumatic rhabdomyolysis induced by streptomycin reinjection]. | 1992 Nov |
|
| Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives. | 1999 Nov-Dec |
|
| Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. | 2000 Feb 1 |
|
| Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. | 2000 Sep |
|
| Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations. | 2001 May |
|
| Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis. | 2002 Aug |
|
| Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. | 2002 Jul |
|
| 3-[4'-bromo-(1,1'-biphenyl)-4-yl]-N, N-dimethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities. | 2002 Nov |
|
| Cryptolepine hydrochloride: a potent antimycobacterial alkaloid derived from Cryptolepis sanguinolenta. | 2003 Apr |
|
| Reversible anosmia after amikacin therapy. | 2003 Dec |
|
| Unbiased quantification of Scarpa's ganglion neurons in aminoglycoside ototoxicity. | 2005 |
|
| Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. | 2005 Nov |
|
| Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis? | 2005 Nov |
|
| Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. | 2006 Apr |
|
| Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis. | 2006 Nov |
|
| Dexamethasone stimulates expression of C-type Natriuretic Peptide in chondrocytes. | 2006 Nov 20 |
|
| Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2. | 2006 Oct 16 |
|
| Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. | 2006 Sep |
|
| Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. | 2007 Dec 19 |
|
| Receptor-induced thiolate couples Env activation to retrovirus fusion and infection. | 2007 Dec 21 |
|
| Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. | 2007 Feb 22 |
|
| ArhGAP9, a novel MAP kinase docking protein, inhibits Erk and p38 activation through WW domain binding. | 2007 Feb 6 |
|
| Inhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency. | 2007 Jan |
|
| Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress. | 2007 Jan 15 |
|
| Identification of putative cis-regulatory elements in Cryptosporidium parvum by de novo pattern finding. | 2007 Jan 9 |
|
| Selective damage of the vestibular apparatus following toxic effects of streptomycin. | 2007 Jul |
|
| Streptomycin action to the mammalian inner ear vestibular organs: comparison between pigmented guinea pigs and rats. | 2007 Jul-Aug |
|
| Effect and mechanism of lipopolysaccharide on allergen-induced interleukin-5 and eotaxins production by whole blood cultures of atopic asthmatics. | 2007 Mar |
|
| Gentamicin suppresses endotoxin-driven TNF-alpha production in human and mouse proximal tubule cells. | 2007 Oct |
|
| Purification of infectious human herpesvirus 6A virions and association of host cell proteins. | 2007 Oct 19 |
|
| Regulation of glycogen synthase kinase 3beta functions by modification of the small ubiquitin-like modifier. | 2008 |
|
| Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. | 2008 |
|
| Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. | 2008 Aug 5 |
|
| Genomic organization, sequence divergence, and recombination of feline immunodeficiency virus from lions in the wild. | 2008 Feb 5 |
|
| (R)-albuterol decreases immune responses: role of activated T cells. | 2008 Jan 14 |
Patents
Sample Use Guides
Intramuscular Route Only
Adults: The preferred site is the upper outer quadrant of the buttock, (i.e., gluteus maximus), or themid-lateral thigh.
Children: It is recommended that intramuscular injections be given preferably in the mid-lateral
muscles of the thigh. In infants and small children the periphery of the upper outer quadrant of the gluteal
region should be used only when necessary, such as in burn patients, in order to minimize the possibility
of damage to the sciatic nerve.
1. TUBERCULOSIS:
Children daily - 20-40 mg/kg
Adults daily - 15 mg/kg
Streptomycin is usually administered daily as a single intramuscular injection. A total dose of not more than 120 g over the course of therapy should be given unless there are no other therapeutic options.
2. TULAREMIA: One to 2 g daily in divided doses for 7 to 14 days until the patient is afebrile for 5 to 7 days.
3. PLAGUE: Two grams of Streptomycin daily in two divided doses should be administered intramuscularly. A minimum of 10 days of therapy is recommended.
4. BACTERIAL ENDOCARDITIS:
a. Streptococcal endocarditis; in penicillin-sensitive alpha and non-hemolytic streptococcal endocarditis (penicillin MIC<0.1 mcg/mL), Streptomycin may be used for 2-week treatment concomitantly with penicillin. The Streptomycin regimen is 1 g b.i.d. for the first week, and 500 mg b.i.d. for the second week. If the patient is over 60 years of age, the dosage should be 500 mg b.i.d. for the entire 2- week period.
b. Enterococcal endocarditis: Streptomycin in doses of 1 g b.i.d. for 2 weeks and 500 mg b.i.d. for an additional 4 weeks is given in combination with penicillin. Ototoxicity may require termination of the Streptomycin prior to completion of the 6-week course of treatment.
5. CONCOMITANT USE WITH OTHER AGENTS: For concomitant use with other agents to which the infecting organism is also sensitive: Streptomycin is considered a secondline agent for the treatment of gram-negative bacillary bactermia, meningitis, and pneumonia; brucellosis; granuloma inguinale; chancroid, and urinary tract infection.
For adults: 1 to 2 grams in divided doses every six to twelve hours for moderate to severe infections. Doses should generally not exceed 2 grams per day.
For children: 20 to 40 mg/kg/day (8 to 20 mg/lb/day) in divided doses every 6 to 12 hours. (Particular care should be taken to avoid excessive dosage in children).
Route of Administration:
Intramuscular
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3688-73-1
Created by
admin on Sat Dec 16 08:44:52 GMT 2023 , Edited by admin on Sat Dec 16 08:44:52 GMT 2023
|
PRIMARY | |||
|
DTXSID40109102
Created by
admin on Sat Dec 16 08:44:52 GMT 2023 , Edited by admin on Sat Dec 16 08:44:52 GMT 2023
|
PRIMARY | |||
|
91867538
Created by
admin on Sat Dec 16 08:44:52 GMT 2023 , Edited by admin on Sat Dec 16 08:44:52 GMT 2023
|
PRIMARY | |||
|
964DE84PV6
Created by
admin on Sat Dec 16 08:44:52 GMT 2023 , Edited by admin on Sat Dec 16 08:44:52 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
